The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states.
about
Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectivesOpen access chemical probes for epigenetic targetsGain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic interventionNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewStructure of the Catalytic Domain of EZH2 Reveals Conformational Plasticity in Cofactor and Substrate Binding Sites and Explains Oncogenic MutationsMutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutationsThe Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.WEE1 tyrosine kinase, a novel epigenetic modifierRecent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer.EZH2 as a potential target in cancer therapy.Histone methylases as novel drug targets: developing inhibitors of EZH2.Genetic lesions in diffuse large B-cell lymphomasAn Alternative Approach to ChIP-Seq Normalization Enables Detection of Genome-Wide Changes in Histone H3 Lysine 27 Trimethylation upon EZH2 Inhibition.Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED.The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.A Multiplexed System for Quantitative Comparisons of Chromatin Landscapes.Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndromeExploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.Targeting EZH2 for cancer therapy: progress and perspective.EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples.Epigenetic modification in gliomas: role of the histone methyltransferase EZH2.Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014).Driver mutations of cancer epigenomes.Citrullination/Methylation Crosstalk on Histone H3 Regulates ER-Target Gene Transcription.Maintaining cell identity: PRC2-mediated regulation of transcription and cancer.Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.Characterization of Inhibitor Binding Through Multiple Inhibitor Analysis: A Novel Local Fitting Method.Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2Building the Connectivity Map of epigenetics: chromatin profiling by quantitative targeted mass spectrometry.Convergent evolution of chromatin modification by structurally distinct enzymes: comparative enzymology of histone H3 Lys²⁷ methylation by human polycomb repressive complex 2 and vSET.The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD).UHRF1: a master regulator in prostate cancer.Structure, mechanism, and regulation of polycomb repressive complex 2.Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin.
P2860
Q26744441-1ADE3009-C92A-47A2-9264-B0DEB1D4418FQ26781872-1483B9C9-2947-4F39-A245-627F05D069E8Q27024233-1D734A44-9C7B-4483-8A6A-0A0BFCE92313Q27304386-781B7FD8-F2D3-480B-9505-5E1583D888BEQ27681082-2242198A-E5CD-4AC5-A0EB-86D2375ECE05Q29147438-0D5B67A3-DF2B-4EEF-B307-DE96C2E168CAQ29615392-CBAE09BC-9D29-40C4-9FA5-3BC542F88A3BQ33915185-17460E66-EC5D-4237-91E1-FBCC92D2DE6EQ34302726-EC853667-9ABE-4750-B754-49E276F1A161Q34335765-DFABEF1B-8644-4787-B7F4-6D8C41478D43Q34991896-8C899D95-1F22-4B11-B811-36BAF52C9FA7Q35222823-968D1E89-E3EA-4734-B8CD-85FCBF23C661Q35510392-D2F53E5F-644F-4B6A-BD7B-FD85DAB9C21FQ35974341-2733322B-9616-403C-8469-4D673FE3B26FQ36201086-A9AA87B3-503A-4D44-AF76-B640D5363D1EQ36245610-970C5B74-8238-4301-A37F-3EA693785F6CQ36250669-D953D324-1AA1-4B72-B6C5-8DA06D662B82Q36450242-CC591CEA-229A-4646-85A6-15223720942EQ36946728-DF63441F-7F6D-4BF3-848D-00C5A29B0ED2Q36956610-605FE135-7382-4426-B854-8C4BCFFCDD6AQ37204063-72A961AD-0A4C-4EBD-9988-13617BF337CCQ37235726-8AF68434-FE1C-4B1E-AE0B-16C08CBD9DDDQ38232172-F68E7774-7B97-471A-AE5E-9D026BA818F1Q38547122-C41B7E73-38CD-491E-91E1-878D6F1889BCQ38639828-8D6CB961-AF70-49A2-BA80-896A1A16D728Q38796261-276B8220-2A2C-40F6-854C-3620D7F92102Q38961785-A673C38E-3691-4BCD-A32C-658CDE813D25Q39457118-CD02337D-A252-45D8-97DB-E86C86F69F8FQ39674247-965993FA-3174-40C0-A1C3-EF0099B66896Q39785596-BA2DCC96-84F6-47CF-961C-AF6517C06B89Q43112629-3B790607-8E4B-4464-BB8E-FD426CDFD107Q45745330-4EC4480B-AB03-4611-AB6D-2ECFC027D9F0Q46382588-3F04E537-68A9-46D0-905F-AC956E7148D1Q46401992-A7BA8135-B4F6-4F4D-9075-A8D934E28B72Q47948466-EB947594-BBE5-46EE-846F-CFAE9958010DQ52313298-75A9B1C1-27B1-4C3C-83C1-610495C08656
P2860
The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
The Y641C mutation of EZH2 alt ...... lysine 27 methylation states.
@en
The Y641C mutation of EZH2 alt ...... lysine 27 methylation states.
@nl
type
label
The Y641C mutation of EZH2 alt ...... lysine 27 methylation states.
@en
The Y641C mutation of EZH2 alt ...... lysine 27 methylation states.
@nl
prefLabel
The Y641C mutation of EZH2 alt ...... lysine 27 methylation states.
@en
The Y641C mutation of EZH2 alt ...... lysine 27 methylation states.
@nl
P2093
P2860
P1433
P1476
The Y641C mutation of EZH2 alt ...... lysine 27 methylation states.
@en
P2093
Kevin W Kuntz
Margaret Porter Scott
Robert A Copeland
Roy M Pollock
Sarah K Knutson
Tim J Wigle
Victoria M Richon
P2860
P304
P356
10.1016/J.FEBSLET.2011.08.018
P407
P577
2011-08-17T00:00:00Z